- Home
- BBIO vs FICO Comparison
BBIO vs FICO Comparison
Compare BBIO & FICO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBIO | FICO |
|---|---|---|
| Founded | 2015 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7B | 41.2B |
| IPO Year | 2019 | 1987 |
Fundamental Metrics
Financial Performance| Metric | BBIO | FICO |
|---|---|---|
| Price | $76.53 | $1,730.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 21 | 12 |
| Target Price | $76.24 | ★ $1,999.83 |
| AVG Volume (30 Days) | ★ 1.8M | 181.6K |
| Earning Date | 10-29-2025 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.78 |
| EPS | N/A | ★ 26.54 |
| Revenue | $353,780,000.00 | ★ $1,990,869,000.00 |
| Revenue This Year | $127.64 | $24.77 |
| Revenue Next Year | $78.38 | $17.55 |
| P/E Ratio | ★ N/A | $65.22 |
| Revenue Growth | ★ 62.46 | 15.91 |
| 52 Week Low | $27.23 | $1,300.00 |
| 52 Week High | $78.44 | $2,217.60 |
Technical Indicators
Market Signals| Indicator | BBIO | FICO |
|---|---|---|
| Relative Strength Index (RSI) | 65.57 | 45.99 |
| Support Level | $75.82 | $1,726.39 |
| Resistance Level | $78.44 | $1,767.90 |
| Average True Range (ATR) | 2.25 | 47.54 |
| MACD | -0.18 | -11.39 |
| Stochastic Oscillator | 76.39 | 18.19 |
Price Performance
Historical ComparisonAbout BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About FICO Fair Isaac Corproation
Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's US-centric credit scores business accounts for most of the firm's revenue and profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.